Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Cryo Cell International (CCEL) Other Operating Expenses: 2010-2025

Historic Other Operating Expenses for Cryo Cell International (CCEL) over the last 16 years, with Q3 2025 value amounting to $2.0 million.

  • Cryo Cell International's Other Operating Expenses fell 1436.36% to $2.0 million in Q3 2025 from the same period last year, while for Aug 2025 it was $8.0 million, marking a year-over-year decrease of 6778.73%. This contributed to the annual value of $8.1 million for FY2024, which is 6751.35% down from last year.
  • As of Q3 2025, Cryo Cell International's Other Operating Expenses stood at $2.0 million, which was down 1436.36% from $2.0 million recorded in Q2 2025.
  • Cryo Cell International's Other Operating Expenses' 5-year high stood at $18.2 million during Q4 2023, with a 5-year trough of $1.8 million in Q4 2024.
  • Its 5-year average for Other Operating Expenses is $3.2 million, with a median of $2.3 million in 2024.
  • Per our database at Business Quant, Cryo Cell International's Other Operating Expenses skyrocketed by 60024.75% in 2023 and then tumbled by 8989.51% in 2024.
  • Quarter analysis of 5 years shows Cryo Cell International's Other Operating Expenses stood at $3.6 million in 2021, then dropped by 27.11% to $2.6 million in 2022, then skyrocketed by 600.25% to $18.2 million in 2023, then tumbled by 89.9% to $1.8 million in 2024, then rose by 8.26% to $2.0 million in 2025.
  • Its Other Operating Expenses stands at $2.0 million for Q3 2025, versus $2.0 million for Q2 2025 and $2.2 million for Q1 2025.